Minerva Neurosciences Stock Forecast, Price & News

+0.17 (+10.18 %)
(As of 09/16/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume736,594 shs
Average Volume972,618 shs
Market Capitalization$78.61 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive NERV News and Ratings via Email

Sign-up to receive the latest news and ratings for Minerva Neurosciences and its competitors with MarketBeat's FREE daily newsletter.

Minerva Neurosciences logo

About Minerva Neurosciences

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson's disease. The company was founded by Rogerio Vivaldi Coelho on April 23, 2007 and is headquartered in Waltham, MA.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.11 out of 5 stars

Medical Sector

443rd out of 1,352 stocks

Pharmaceutical Preparations Industry

217th out of 665 stocks

Analyst Opinion: 3.3Community Rank: 4.8Dividend Strength: 0.0Insider Behavior: 2.5Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Minerva Neurosciences (NASDAQ:NERV) Frequently Asked Questions

Is Minerva Neurosciences a buy right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Minerva Neurosciences in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Minerva Neurosciences stock.
View analyst ratings for Minerva Neurosciences
or view top-rated stocks.

What stocks does MarketBeat like better than Minerva Neurosciences?

Wall Street analysts have given Minerva Neurosciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Minerva Neurosciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

When is Minerva Neurosciences' next earnings date?

Minerva Neurosciences is scheduled to release its next quarterly earnings announcement on Monday, November 1st 2021.
View our earnings forecast for Minerva Neurosciences

How were Minerva Neurosciences' earnings last quarter?

Minerva Neurosciences, Inc. (NASDAQ:NERV) announced its quarterly earnings results on Monday, August, 2nd. The biopharmaceutical company reported ($0.25) EPS for the quarter, missing the Zacks' consensus estimate of ($0.17) by $0.08.
View Minerva Neurosciences' earnings history

How has Minerva Neurosciences' stock price been impacted by Coronavirus (COVID-19)?

Minerva Neurosciences' stock was trading at $6.36 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, NERV shares have decreased by 71.1% and is now trading at $1.84.
View which stocks have been most impacted by COVID-19

What price target have analysts set for NERV?

2 analysts have issued 1 year target prices for Minerva Neurosciences' stock. Their forecasts range from $3.00 to $10.00. On average, they expect Minerva Neurosciences' share price to reach $6.50 in the next twelve months. This suggests a possible upside of 253.3% from the stock's current price.
View analysts' price targets for Minerva Neurosciences
or view top-rated stocks among Wall Street analysts.

Who are Minerva Neurosciences' key executives?

Minerva Neurosciences' management team includes the following people:
  • Rémy Henri Luthringer, Executive Chairman & Chief Executive Officer
  • Joseph Reilly, Chief Operating Officer & Senior Vice President
  • Geoff Race, Executive VP, Chief Financial & Business Officer
  • Michael Davidson, Chief Medical Officer
  • Jay B. Saoud, Senior Vice President, Head-Research & Development

Who are some of Minerva Neurosciences' key competitors?

What other stocks do shareholders of Minerva Neurosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Minerva Neurosciences investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), PTC Therapeutics (PTCT), Immunomedics (IMMU), VBI Vaccines (VBIV), Dynavax Technologies (DVAX), Gilead Sciences (GILD), Moderna (MRNA), T2 Biosystems (TTOO) and Advanced Micro Devices (AMD).

What is Minerva Neurosciences' stock symbol?

Minerva Neurosciences trades on the NASDAQ under the ticker symbol "NERV."

Who are Minerva Neurosciences' major shareholders?

Minerva Neurosciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (9.59%), Millennium Management LLC (3.03%), Dimensional Fund Advisors LP (2.50%), Renaissance Technologies LLC (2.35%), Morgan Stanley (1.48%) and Morgan Stanley (1.48%). Company insiders that own Minerva Neurosciences stock include Frederick W Ahlholm, Geoff Race, Heek G Jan Van, Joseph H Reilly and Remy Luthringer.
View institutional ownership trends for Minerva Neurosciences

Which major investors are selling Minerva Neurosciences stock?

NERV stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., State Street Corp, Vanguard Group Inc., Northern Trust Corp, Morgan Stanley, Morgan Stanley, Geode Capital Management LLC, and Bridgeway Capital Management LLC. Company insiders that have sold Minerva Neurosciences company stock in the last year include Frederick W Ahlholm, Geoff Race, Joseph H Reilly, and Remy Luthringer.
View insider buying and selling activity for Minerva Neurosciences
or view top insider-selling stocks.

Which major investors are buying Minerva Neurosciences stock?

NERV stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, Renaissance Technologies LLC, GSA Capital Partners LLP, Ergoteles LLC, Tibra Equities Europe Ltd, Jump Financial LLC, XTX Topco Ltd, and LMR Partners LLP.
View insider buying and selling activity for Minerva Neurosciences
or or view top insider-buying stocks.

How do I buy shares of Minerva Neurosciences?

Shares of NERV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Minerva Neurosciences' stock price today?

One share of NERV stock can currently be purchased for approximately $1.84.

How much money does Minerva Neurosciences make?

Minerva Neurosciences has a market capitalization of $78.61 million and generates $41.18 million in revenue each year. The biopharmaceutical company earns $1.94 million in net income (profit) each year or $0.05 on an earnings per share basis.

How many employees does Minerva Neurosciences have?

Minerva Neurosciences employs 11 workers across the globe.

What is Minerva Neurosciences' official website?

The official website for Minerva Neurosciences is

Where are Minerva Neurosciences' headquarters?

Minerva Neurosciences is headquartered at 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451.

How can I contact Minerva Neurosciences?

Minerva Neurosciences' mailing address is 1601 TRAPELO ROAD SUITE 286, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at (617) 600-7373 or via email at [email protected]

This page was last updated on 9/16/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.